Stocktoria
BGM Group Ltd. BGM
BGM Group Ltd. (BGM) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 3.01% (safety: no dividend). FY2024 revenue was $37.9M at a -52.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.396 |
| Retained earnings / assets | 0.082 |
| EBIT / assets | -0.011 |
| Equity / liabilities | 4.949 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BGM | BGM Group Ltd. | 5/9 | 7.99 | — | +51.1% |
| SBFM | Sunshine Biopharma Inc. | 4/9 | -1.63 | — | +4.1% |
| ETST | Earth Science Tech, Inc. | 4/9 | — | 12.7 | +7.8% |
| VRCA | Verrica Pharmaceuticals Inc. | 5/9 | -19.42 | — | — |
| BFRI | Biofrontera Inc. | 1/9 | -15.24 | — | +11.7% |
| WVE | Wave Life Sciences Ltd. | 2/9 | 1.15 | — | -60.5% |
| XLO | Xilio Therapeutics, Inc. | 4/9 | -6.58 | — | — |
About BGM Group Ltd.
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform. BGM Group Ltd. is based in Chengdu, China.
FAQ
Is BGM financially healthy?
BGM Group Ltd.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does BGM pay a dividend, and is it safe?
Yes. BGM Group Ltd. pays a dividend yielding about 3.01% with a None payout ratio, rated “no dividend” for safety.
How profitable is BGM?
In FY2024, BGM Group Ltd. had a net margin of -52.6% and a return on equity of -5.1%.
Is BGM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BGM Group Ltd.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a dividend yield of 3.01%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2024-09-30. Facts plus Stocktoria's own computed scores — not investment advice.